Following a re-submission.
Tipranavir (Aptivus) in combination with low dose ritonavir is accepted for restricted use within NHS Scotland for the treatment of HIV-1 infection in highly pre-treated adult patients with virus resistant to multiple protease inhibitors.
At 48 weeks, tipranavir, in combination with low dose ritonavir, showed a significant improvement in the reduction of viral load compared with other protease inhibitor plus ritonavir regimens. Although the overall rate and type of adverse events were similar, tipranavir had a higher incidence of hepatotoxicity, hyperlipidaemia, bleeding events and rash.
Tipranavir is more expensive than other protease inhibitors and it is restricted to patients with a tipranavir mutation score of less than 4.
Download detailed advice47KB (PDF)
- Medicine name:
- tipranavir, 250 mg capsule (Aptivus)
- SMC ID:
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Submission type
- Date advice published:
- 11 September 2006